Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.61 USD | -6.12% | -10.56% | -28.44% |
Valuation
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Capitalization 1 | 433.3 | 436.6 | 152.6 | 109.9 | - | - |
Enterprise Value (EV) 1 | 433.3 | 206.3 | 156.9 | 136.5 | 80.15 | 28.69 |
P/E ratio | -5.53 x | -2.85 x | -1.29 x | -1.04 x | -1.15 x | -1.27 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | 76.9 x | 11 x |
EV / Revenue | - | - | - | - | 56.1 x | 2.87 x |
EV / EBITDA | - | -2.27 x | -1.28 x | -1.13 x | -0.53 x | -0.15 x |
EV / FCF | -5.93 x | -2.2 x | -1.55 x | -1.13 x | -0.61 x | -0.29 x |
FCF Yield | -16.9% | -45.4% | -64.6% | -88.2% | -164% | -348% |
Price to Book | - | - | - | - | - | - |
Nbr of stocks (in thousands) | 37,290 | 65,649 | 67,806 | 68,260 | - | - |
Reference price 2 | 11.62 | 6.650 | 2.250 | 1.610 | 1.610 | 1.610 |
Announcement Date | 3/14/22 | 3/23/23 | 3/20/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | 1.429 | 10 |
EBITDA 1 | - | - | - | -90.89 | -122.5 | -121.3 | -150.8 | -189.7 |
EBIT 1 | -10.42 | -43.37 | -69.02 | -93.42 | -126 | -119.6 | -126.9 | -123.4 |
Operating Margin | - | - | - | - | - | - | -8,879.89% | -1,234.47% |
Earnings before Tax (EBT) 1 | - | -43.34 | -68.9 | -92.09 | -117.9 | -113.4 | -119.3 | -123.5 |
Net income 1 | - | -49.26 | -70.13 | -92.09 | -117.9 | -113.4 | -119.3 | -123.5 |
Net margin | - | - | - | - | - | - | -8,347.72% | -1,234.68% |
EPS 2 | -109.8 | -230.6 | -2.100 | -2.330 | -1.750 | -1.555 | -1.396 | -1.266 |
Free Cash Flow 1 | - | - | -73.04 | -93.61 | -101.4 | -120.3 | -131.7 | -99.8 |
FCF margin | - | - | - | - | - | - | -9,221.04% | -997.98% |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - | - |
Announcement Date | 11/6/20 | 3/25/21 | 3/14/22 | 3/23/23 | 3/20/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBIT 1 | -18.31 | -22.8 | -21.79 | -24.1 | -24.72 | -30.42 | -32.17 | -35.32 | -28.12 | -32.33 | -28.5 | -27.95 | -28 | -26.79 | -28.96 |
Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -18.25 | -22.74 | -21.66 | -23.79 | -23.91 | -28.43 | -29.98 | -33.19 | -26.26 | -30.8 | -27.26 | -26.62 | -26.57 | -26.03 | -28.2 |
Net income 1 | -18.25 | -22.74 | -21.66 | -23.79 | -23.91 | -28.43 | -29.98 | -33.19 | -26.26 | -30.8 | -27.26 | -26.62 | -26.57 | -26.03 | -28.2 |
Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EPS 2 | -0.4900 | -0.6100 | -0.5800 | -0.6300 | -0.5300 | -0.4300 | -0.4500 | -0.4900 | -0.3900 | -0.4500 | -0.4069 | -0.3800 | -0.3466 | -0.3300 | -0.3380 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 3/14/22 | 5/12/22 | 8/11/22 | 11/10/22 | 3/23/23 | 5/11/23 | 8/10/23 | 11/7/23 | 3/20/24 | 5/9/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | 4.3 | 26.6 | - | - |
Net Cash position 1 | - | - | 230 | - | - | 29.8 | 81.2 |
Leverage (Debt/EBITDA) | - | - | - | -0.0351 x | -0.219 x | - | - |
Free Cash Flow 1 | - | -73 | -93.6 | -101 | -120 | -132 | -99.8 |
ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - | - |
Capex 1 | 4.16 | 3.89 | 8.46 | 1.07 | 4.66 | 4.52 | 5.06 |
Capex / Sales | - | - | - | - | - | 316.19% | 50.58% |
Announcement Date | 3/25/21 | 3/14/22 | 3/23/23 | 3/20/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-28.44% | 117M | |
+64.92% | 62.59B | |
-1.85% | 41.18B | |
+44.76% | 40.29B | |
-8.93% | 27.9B | |
+13.05% | 26.21B | |
-21.96% | 19.09B | |
+4.21% | 13.08B | |
+25.74% | 12.26B | |
+27.42% | 12.05B |
- Stock Market
- Equities
- VOR Stock
- Financials Vor Biopharma Inc.